Discover
ZBIO
Zenas BioPharma, Inc.
32.36
1 x 31.40
1 x 35.71
bid
ask
+
1.66
5.41%
185 @ 04:00 PM
32.30 -0.06 (0.19%)
| Ytd | -10.88% | |
| 1y | 126.14% |
30.77
day range
34.03
13.50
52 week range
44.60
| Open | 31.37 | Prev Close | 30.70 | Low | 30.77 | High | 34.03 | Mkt Cap | 1.44B |
| Vol | 1.62M | Avg Vol | 772.06K | EPS | -5.03 | P/E | -6.43 | Forward P/E | -12.69 |
| Beta | -0.96 | Short Ratio | 13.37 | Inst. Own | 90.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 22.12 | 200-d Avg | 25.44 | 1yr Est | 42.13 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.89 | N/A | N/A | N/A |
| 2026-05-13 | 2026-03 | -1.37 | -1.46 | -0.09 | -6.57% |
| 2026-03-16 | 2025-12 | -1 | -1.1 | -0.1 | -9.85% |
| 2025-11-12 | 2025-09 | -0.87 | -1.22 | -0.35 | -40.23% |
| 2025-08-12 | 2025-06 | -1.02 | -1.25 | -0.23 | -22.55% |
| 2025-05-15 | 2025-03 | -1.11 | -0.8 | 0.31 | 27.93% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2026-03-17 | Citigroup | Upgrade | Buy | Buy |
| 2026-03-17 | Guggenheim | Upgrade | Buy | Buy |
| 2026-03-17 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2026-03-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-12 | ALLEN PATRICIA L | Director | 19.86K | Purchase |
| 2024-09-15 | ENAVATE SCIENCES GP, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-10-08 | ENRIGHT PATRICK G. | Director | 0.00 | Purchase |
| 2026-03-30 | FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | 0.00 | Purchase |
| 2026-03-30 | LU HONGBO B | Director | 0.00 | Purchase |
| 2026-05-17 | MOULDER LEON OLIVER JR. | Chief Executive Officer | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 9.08M | 0.00 | 14.39% |
| 2025-12-30 | SR ONE CAPITAL MANAGEMENT, LP | 5.04M | 0.00 | 7.98% |
| 2026-03-30 | NEA Management Company, LLC | 4.02M | 0.00 | 6.37% |
| 2026-03-30 | Enavate Sciences GP, LLC | 3.92M | 0.00 | 6.21% |
| 2026-03-30 | Federated Hermes Inc | 3.13M | 0.00 | 4.95% |
| 2026-03-30 | Polar Capital Holdings PLC | 2.55M | 0.00 | 4.04% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | American Funds SMALLCAP World A | 2.43M | 0.00 | 3.86% |
| 2026-04-29 | Polar Capital Biotech S Inc | 2.41M | 0.00 | 3.82% |
| 2026-03-30 | Federated Hermes Kaufmann R | 1.82M | 0.00 | 2.89% |
| 2026-03-30 | Federated Hermes Kaufmann Growth | 1.82M | 0.00 | 2.89% |
| 2026-03-30 | Federated Hermes Kaufmann Small Cap Grow | 1.25M | 0.00 | 1.98% |
| 2026-03-30 | Federated Hermes Kaufmann Small Cap A | 1.25M | 0.00 | 1.98% |
Dividend
| Dividend | Date |
|---|---|
| 0.002 | 2019-12-24 |
| 0.017 | 2019-09-25 |
| 0.015 | 2019-06-25 |
| 0.013 | 2019-03-20 |
| 0.005001 | 2018-12-26 |
Split
| Split | Date |
|---|---|
| 1 : 2 | 2018-05-24 |